Summer Street Reiterates Buy on Vertex Pharmaceuticals (VRTX)
VRTX has been the subject of a number of other recent research reports. Analysts at Barclays Capital (NYSE: BCS) raised their price target on shares of Vertex Pharmaceuticals from $44.00 to $77.00 in a research note to investors on Tuesday. They now have an “overweight” rating on the stock. Separately, analysts at Wells Fargo & Co. (NYSE: WFC) upgraded shares of Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note to investors on Tuesday. Finally, analysts at Morgan Stanley (NYSE: MS) upgraded shares of Vertex Pharmaceuticals from an “underweight” rating to an “equal weight” rating in a research note to investors on Tuesday. They now have a $51.00 price target on the stock.
Shares of Vertex Pharmaceuticals opened at 64.16 on Tuesday. Vertex Pharmaceuticals has a 52 week low of $26.50 and a 52 week high of $64.50. The company has a market cap of $13.529 billion and a P/E ratio of 45.63.
Vertex Pharmaceuticals last announced its earnings results on Thursday, April 26th. The company reported $0.43 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.57 by $0.14. The company’s quarterly revenue was up 496.5% on a year-over-year basis. On average, analysts predict that Vertex Pharmaceuticals will post $0.72 earnings per share next quarter.
Vertex Pharmaceuticals Incorporated (Vertex) is in the business of discovering, developing, manufacturing and commercializing small molecule drugs for the treatment of serious diseases.